Yumanity Therapeutics GAAP EPS of -$0.31, revenue of $1.4M

Stock Information for Yumanity Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Yumanity Therapeutics Inc.

Yumanity Therapeutics Declares Special Dividend In Connection with Proposed Asset Sale to Janssen and Merger with Kineta
Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
Yumanity Therapeutics Announces Effectiveness of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kineta, Inc.
Yumanity Therapeutics Announces Filing of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kineta
Yumanity Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Developments
INVESTIGATION NOTICE: Halper Sadeh LLP Investigates TPTX, DRE, CVET, YMTX
YUMANITY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Yumanity Therapeutics, Inc. - YMTX
INVESTIGATION ALERT: Halper Sadeh LLP Investigates YMTX, TMX, MN, VSAT

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.